Orchid Wins First Certification for HLA Testing
PRINCETON, N.J., Sept. 20 -- Orchid BioSciences Inc. said that its GeneScreen business unit has received certification by the American Society of Histocompatibility and Immunogenetics (ASHI) to conduct commercial human leukocyte antigen (HLA) testing on the LabMap platform of Luminex Corp. Orchid is the first CLIA-approved laboratory to be awarded this accreditation, which it expects will allow it to significantly reduce turn-around time for its HLA-DR tissue typing services both for single-sample testing and for donor recruitment drives. HLA typing is the first step for patients and potential donors in the matching process for stem cell transplantation.
Luminex's open platform LabMap technology can perform up to 100 assays simultaneously on a small quantity of DNA with the capability for both medium and high throughput assay applications. This system combines the use of cost effective microsphere-based assays with small lasers, advanced digital signal processors and proprietary software to offer greater speed, precision and flexibility over other bioassay technologies.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024